RET and non-small cell lung carcinoma: Activity of MKIs in RET fusion-positive NSCLC has been reported in pre-clinical cancer models [31,36,58,59], in retrospective case series [45,60] and in phase I and phase II trials [43,49,54,61,62,63,64].